# The Hemodynamic Response to Prolonged Dobutamine Infusion

Study · id `cardio:ct-nct01042873` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01042873](<https://clinicaltrials.gov/study/NCT01042873>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01042873

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT01042873. Allocation not applicable; no masking; primary purpose other. Start 2010-01 (registry gives no type); primary completion 2020-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose other
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT01042873, source copy `cardio:ctgov-nct01042873-2018-06-12`, retrieved 2026-10-26)
- Start date: 2010-01 (registry gives no type) (ClinicalTrials.gov record NCT01042873, source copy `cardio:ctgov-nct01042873-2018-06-12`, retrieved 2026-10-26)
- Primary completion: 2020-12 (anticipated) (ClinicalTrials.gov record NCT01042873, source copy `cardio:ctgov-nct01042873-2018-06-12`, retrieved 2026-10-26)
- Completion: 2021-12 (anticipated) (ClinicalTrials.gov record NCT01042873, source copy `cardio:ctgov-nct01042873-2018-06-12`, retrieved 2026-10-26)
- Countries: Israel (ClinicalTrials.gov record NCT01042873, source copy `cardio:ctgov-nct01042873-2018-06-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01042873-2018-06-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Hemodynamic Response to Prolonged Dobutamine Infusion
- Condition: Healthy
- Condition: Heart Failure
- Intervention (Drug): 3 hours intravenous dobutamine
- Lead sponsor: Hadassah Medical Organization
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Hadassah Medical Organization (`cardio:org-hadassah-medical-organization`)

## Provenance

Content hash: 59085db6059e447b2ed8a4b709d8fa48b746cf448ca73549ec5210654d88feb3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
